CD19 and B-cell non-Hodgkin lymphoma: Blinatumomab, a CD19 × CD3 bispecific T-cell engager already approved for B-cell acute lymphoblastic leukemia (B-ALL), has also shown activity in certain B-cell non-Hodgkin lymphoma subtypes.